ESTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 31 cases where ESTA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ESTA's RSI Oscillator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ESTA as a result. In 82 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ESTA just turned positive on October 20, 2026. Looking at past instances where ESTA's MACD turned positive, the stock continued to rise in 45 of 53 cases over the following month. The odds of a continued upward trend are 85%.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where ESTA advanced for three days, in 240 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for ESTA moved below the 200-day moving average on October 08, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for ESTA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ESTA's P/B Ratio (87.611) is very high in comparison to the industry average of (2.874). P/E Ratio (-50.016) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (8.749) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. ESTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The Stochastic Oscillator for NTRA moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 25 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 33 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
NTRA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on NTRA as a result. In 82 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 245 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 228 of 286 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.762) is normal, around the industry mean (66.046). NTRA's P/E Ratio (-297.311) is considerably lower than the industry average of (2.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ESTA | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 8 | |
SMR RATING 1..100 | 99 | 94 | |
PRICE GROWTH RATING 1..100 | 62 | 34 | |
P/E GROWTH RATING 1..100 | 15 | 90 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (6) in the Biotechnology industry is in the same range as ESTA (13) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ESTA’s over the last 12 months.
NTRA's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for ESTA (100) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than ESTA’s over the last 12 months.
NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as ESTA (99) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ESTA’s over the last 12 months.
NTRA's Price Growth Rating (34) in the Biotechnology industry is in the same range as ESTA (62) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ESTA’s over the last 12 months.
ESTA's P/E Growth Rating (15) in the Medical Specialties industry is significantly better than the same rating for NTRA (90) in the Biotechnology industry. This means that ESTA’s stock grew significantly faster than NTRA’s over the last 12 months.
| ESTA | NTRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 66% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 66% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 83% |
| Advances ODDS (%) | 1 day ago 78% | 2 days ago 80% |
| Declines ODDS (%) | 4 days ago 77% | 9 days ago 76% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 80% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ESTA’s FA Score shows that 2 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ESTA’s TA Score shows that 5 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
ESTA (@Medical/Nursing Services) experienced а +3.52% price change this week, while NTRA (@Medical Specialties) price change was -0.84% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.29%. For the same industry, the average monthly price growth was -6.63%, and the average quarterly price growth was +42.53%.
ESTA is expected to report earnings on Oct 29, 2026.
NTRA is expected to report earnings on Nov 05, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.29% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, ESTA has been loosely correlated with NPCE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ESTA jumps, then NPCE could also see price increases.
| Ticker / NAME | Correlation To ESTA | 1D Price Change % | ||
|---|---|---|---|---|
| ESTA | 100% | +1.99% | ||
| NPCE - ESTA | 46% Loosely correlated | +0.69% | ||
| RDNT - ESTA | 41% Loosely correlated | +2.70% | ||
| NVST - ESTA | 39% Loosely correlated | +3.36% | ||
| NTRA - ESTA | 37% Loosely correlated | -2.91% | ||
| ISRG - ESTA | 36% Loosely correlated | +3.67% | ||
More | ||||
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -2.91% | ||
| ADPT - NTRA | 55% Loosely correlated | -3.63% | ||
| NEO - NTRA | 54% Loosely correlated | -3.81% | ||
| GH - NTRA | 54% Loosely correlated | -2.23% | ||
| ISRG - NTRA | 53% Loosely correlated | +3.67% | ||
| TMO - NTRA | 48% Loosely correlated | -2.52% | ||
More | ||||